A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- River Vision Development Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT02103283
- Locations
- 🇺🇸
David A Eichenbaum, MD, St. Petersburg, Florida, United States
🇺🇸Diana Do, MD, Omaha, Nebraska, United States
🇺🇸David S Boyer, Beverley Hills, California, United States
© Copyright 2024. All Rights Reserved by MedPath